Welcome to LookChem.com Sign In|Join Free
  • or
2,2-Dimethyl-succinic acid 4-{(3S,4aR,6aR,6bR,8aS,12bS,14aR,14bR)-8a-[(S)-1-(3-carboxy-3-methyl-butyryloxymethyl)-3-methyl-butylcarbamoyl]-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12b,13,14,14a,14b-icosahydro-picen-3-yl} ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

872584-92-4

Post Buying Request

872584-92-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

872584-92-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 872584-92-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,2,5,8 and 4 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 872584-92:
(8*8)+(7*7)+(6*2)+(5*5)+(4*8)+(3*4)+(2*9)+(1*2)=214
214 % 10 = 4
So 872584-92-4 is a valid CAS Registry Number.

872584-92-4Upstream product

872584-92-4Downstream Products

872584-92-4Relevant academic research and scientific papers

Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents

Yu, Donglei,Sakurai, Yojiro,Chen, Chin-Ho,Chang, Fang-Rong,Huang, Li,Kashiwada, Yoshiki,Lee, Kuo-Hsiung

, p. 5462 - 5469 (2006)

In a continuing structure-activity relationship study of potent anti-HIV agents, seven new triterpene derivatives were designed, synthesized, and evaluated for in vitro antiviral activity. Among them, moronic acid derivatives 19, 20, and 21 showed significant activity in HIV-1 infected H9 lymphocytes. Compounds 19 and 20 were also evaluated against HIV-1 NL4-3 and drug resistant strains in the MT-4 cell line. Compounds 19 and 20 showed better antiviral profiles than the betulinic acid analogue 8 (PA-457), which has successfully completed a Phase IIa clinical trial. Compound 20 showed potent anti-HIV activity with EC50 values of 0.0085 μM against NL4-3, 0.021 μM against PI-R (a multiple protease inhibitor resistant strain), and 0.13 μM against FHR-2 (an HIV strain resistant to 8). Promising compound 20 has become a new lead for modification, and further development of 20-related compounds as clinical trial candidates is warranted.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 872584-92-4